OncoMatch/Clinical Trials/NCT06667154
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
Is NCT06667154 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Low-dose nivolumab combined with platinum-based doublet chemotherapy for lung cancer, nonsmall cell.
Treatment: Low-dose nivolumab combined with platinum-based doublet chemotherapy — The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant immunotherapy combined with platinum doublet.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
Negative for EGFR gene expression. Positive for EGFR gene expression [excluded].
Required: ALK wild-type
Negative for ALK protein expression. Positive for ALK protein expression [excluded].
Required: ROS1 wild-type
Negative for ROS1 protein expression. Positive for ROS1 protein expression [excluded].
Required: PD-L1 (CD274) expression documented and assessable (documented and assessable)
PD-L1 protein expression documented and assessable. No available data on PD-L1 protein expression [excluded].
Disease stage
Required: Stage IB, II, IIIA
Excluded: Stage IA, IIIB N3, IIIC, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Lab requirements
Blood counts
Hemoglobin: ≥ 9.0 g/dL; Absolute neutrophil count: ≥ 1.5 × 10^9 /L; Platelet count: ≥ 100 × 10^9 /L. G-CSF, platelet transfusions, and blood transfusions are not permitted to meet these values.
Kidney function
Creatinine clearance: ≥ 50 mL/min (calculated using the Cockcroft and Gault formula).
Liver function
Serum bilirubin: ≤ 1.5 × upper limit of normal (ULN), except for participants with confirmed Gilbert syndrome, who may be included upon physician consultation. ALT and AST: ≤ 2.5 × ULN.
Adequate organ and bone marrow function as defined below: Hemoglobin: ≥ 9.0 g/dL; Absolute neutrophil count: ≥ 1.5 × 10^9 /L; Platelet count: ≥ 100 × 10^9 /L; Serum bilirubin: ≤ 1.5 × upper limit of normal (ULN), except for participants with confirmed Gilbert syndrome, who may be included upon physician consultation. ALT and AST: ≤ 2.5 × ULN. Creatinine clearance: ≥ 50 mL/min (calculated using the Cockcroft and Gault formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify